Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

Abstract:
Carigent Therapeutics, Inc., announced today that the National Cancer Institute of the National Institutes of Health has awarded Carigent a one-year, $153,000 Phase I Small Business Innovation Research (SBIR) grant to advance preclinical development of an innovative, long-circulating nanoparticle therapeutic that targets the specific molecular lesions in non-Hodgkin's lymphoma (NHL) patients.

Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

New Haven, CT | Posted on January 16th, 2008

Carigent's novel therapeutic approach is based on the company's proprietary technology for engineering biodegradable nanoparticles with exceptionally high-density surface modifications. The platform enables Carigent to design customized, multifunctional nanoscale carriers with the unique combined capability of:
Tethering multiple "functional groups" such as targeting ligands, diagnostic imaging agents, and polyethylene glycol (PEG) to the nanoparticle surface at previously unattainable densities, and Encapsulating single or combined therapeutic and/or diagnostic agents inside the nanoparticle for sustained, controlled release directly into targeted (i.e., diseased) tissues and cells.

"Non-Hodgkin's lymphoma has one of the fastest-growing incidence rates among cancers and is now the sixth most common cancer in the U.S.," said Seth Feuerstein, MD, JD, President and a co-founder of Carigent. "As we accelerate development of Carigent's engineered nanoparticle therapeutics to address unmet needs in cancer treatment, we are grateful for this financial support from the National Cancer Institute and the additional validation it provides Carigent's versatile nanoparticle delivery technology. The ability to modify particles for targeting as well as increased circulation time is what makes this an exciting project for the field."

####

About Carigent Therapeutics, Inc.
Carigent Therapeutics, Inc. is a biotechnology company developing and commercializing safer and more effective therapeutic and diagnostic products based on the company’s platform technology: Nanoparticles that enable delivery and controlled release of therapeutic and diagnostic agents into specific locations within the body and tissues. The company’s products and services are based on novel nanotechnology developed at Yale University that provides the unique capability of tethering agents for targeting, imaging, and increased circulation time at unprecedented densities to the surface of biodegradable polymer nanoparticles, resulting in drugs that bind to their targets more effectively, are delivered at a higher concentration to the desired location, and/or remain in the bloodstream longer than other nanotechnology-based drugs. The Carigent technology is broadly applicable across a wide variety of disease states and supports multiple types of targeting strategies and carrier designs for existing drugs as well as new drugs in development. Carigent’s initial product development programs are focused on cancer therapeutics. In parallel, Carigent provides access to its nanoparticle drug delivery technology through collaborations and partnerships with pharmaceutical, biotechnology, and diagnostics companies. Carigent was established in 2007 and is based in New Haven, Connecticut.

For more information, please click here

Contacts:
Mary Moynihan
M2Friend Biocommunications
(802) 951-9600

Copyright © Carigent Therapeutics, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Leti Develops World’s First Micro-Coolers for CERN Particle Detectors: Leti Design, Fabrication and Packaging Expertise Extends to Very Large Scientific Instruments December 11th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Device makes power conversion more efficient: New design could dramatically cut energy waste in electric vehicles, data centers, and the power grid December 8th, 2017

Govt.-Legislation/Regulation/Funding/Policy

Wheat gets boost from purified nanotubes: Rice University toxicity study shows plant growth enhanced by -- but only by -- purified nanotubes December 6th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Chinese market opens up for Carbodeon nanodiamonds: Carbodeon granted Chinese Patent for Nanodiamond-containing Thermoplastic Thermal Compounds December 4th, 2017

Researchers advance technique to detect ovarian cancer: Rice, MD Anderson use fluorescent carbon nanotube probes to achieve first in vivo success November 30th, 2017

Nanomedicine

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Copper will replace toxic palladium and expensive platinum in the synthesis of medications: The effectiveness of copper nanoparticles as a catalyst has been proven December 5th, 2017

Announcements

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Leti Develops World’s First Micro-Coolers for CERN Particle Detectors: Leti Design, Fabrication and Packaging Expertise Extends to Very Large Scientific Instruments December 11th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Device makes power conversion more efficient: New design could dramatically cut energy waste in electric vehicles, data centers, and the power grid December 8th, 2017

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Wheat gets boost from purified nanotubes: Rice University toxicity study shows plant growth enhanced by -- but only by -- purified nanotubes December 6th, 2017

Researchers advance technique to detect ovarian cancer: Rice, MD Anderson use fluorescent carbon nanotube probes to achieve first in vivo success November 30th, 2017

Fast flowing heat in graphene heterostructures: Surprisingly fast heat flow from graphene to its surrounding November 29th, 2017

Tiny robots step closer to treating hard-to-reach parts of the body November 25th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project